Celularity Inc. received notice from Nasdaq for late filing of its Q1 2025 report, affecting compliance with listing rules.
Quiver AI Summary
Celularity Inc. announced that it received a notification from Nasdaq regarding its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which puts the company in non-compliance with Nasdaq Listing Rule 5250(c)(1). While this notice does not immediately affect the listing or trading of the company’s shares, Nasdaq has given Celularity 60 days to submit a compliance plan. If accepted, the company could receive an extension until November 17, 2025, to meet the listing requirements. Celularity is actively working to complete its overdue report and aims to fulfill its SEC reporting obligations. Celularity focuses on developing advanced biomaterial products and cell therapies derived from postpartum placentas to address medical needs.
Potential Positives
- Nasdaq's notice does not have an immediate effect on the listing or trading of the Company’s shares, indicating that there is no immediate risk to the company’s market position.
- Celularity has been given a 60-day period to submit a plan for regaining compliance with Nasdaq Listing Rules, providing a clear path forward for the company.
- The Company is actively working on completing its Form 10-Q, demonstrating commitment to resolving the compliance issue in a timely manner.
Potential Negatives
- Failure to timely file its Quarterly Report on Form 10-Q puts Celularity Inc. in non-compliance with Nasdaq Listing Rule 5250(c)(1), which could reflect negatively on its operational management and governance.
- The Company has a limited timeframe of 60 calendar days to submit a compliance plan, indicating potential instability and urgency that may concern investors.
- While the notice does not immediately affect trading, the ongoing compliance issues could erode investor confidence and raise questions about the Company’s financial health and transparency.
FAQ
What compliance issue did Celularity face with Nasdaq?
Celularity was notified by Nasdaq for not timely filing its Quarterly Report on Form 10-Q.
What is the deadline for Celularity to regain compliance?
Celularity has 60 calendar days to submit a compliance plan to Nasdaq.
Will Celularity's stock listing be affected by this notice?
The Nasdaq notice has no immediate effect on the listing or trading of Celularity's shares.
What does Celularity intend to do to resolve the filing issue?
Celularity continues to work diligently to complete its Form 10-Q for timely compliance with SEC reporting.
What is the focus of Celularity's business?
Celularity specializes in developing advanced biomaterial products and placental-derived cell therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CELU Hedge Fund Activity
We have seen 12 institutional investors add shares of $CELU stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NATIONAL BANK OF CANADA /FI/ added 48,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $83,040
- CITADEL ADVISORS LLC added 46,946 shares (+inf%) to their portfolio in Q1 2025, for an estimated $81,216
- ROYAL BANK OF CANADA added 38,000 shares (+168.9%) to their portfolio in Q1 2025, for an estimated $65,740
- CRESSET ASSET MANAGEMENT, LLC removed 35,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $72,800
- GROUP ONE TRADING LLC added 26,243 shares (+inf%) to their portfolio in Q1 2025, for an estimated $45,400
- CENTERSTAR ASSET MANAGEMENT, LLC removed 22,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $38,060
- ACADIAN ASSET MANAGEMENT LLC added 20,158 shares (+inf%) to their portfolio in Q1 2025, for an estimated $34,873
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.
The Notice received from Nasdaq has no immediate effect on the listing or trading of the Company’s shares. Nasdaq has provided the Company 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company an exception until November 17, 2025, to regain compliance with the Nasdaq Listing Rules.
The Company continues to work diligently to complete its Form 10-Q for the period ended March 31, 2025, after which the Company anticipates maintaining compliance with its SEC reporting obligations.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com .
Forward-Looking Statements
This press release includes “forward-looking statements” (as defined under Federal securities laws). These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,” and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
[email protected]